Total Payments
$52,072
2024 Payments
$3,730
Companies
11
Transactions
97
Medicare Patients
994
Medicare Billing
$299,112
Payment Breakdown by Category
Other$32,072 (61.6%)
Consulting$9,825 (18.9%)
Travel$6,704 (12.9%)
Food & Beverage$3,342 (6.4%)
Education$128.90 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Honoraria | $27,122 | 17 | 52.1% |
| Consulting Fee | $9,825 | 6 | 18.9% |
| Travel and Lodging | $6,704 | 25 | 12.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,950 | 2 | 9.5% |
| Food and Beverage | $3,342 | 43 | 6.4% |
| Education | $128.90 | 4 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | $15,820 | 37 | $0 (2018) |
| Amylyx Pharmaceuticals, Inc. | $15,542 | 19 | $0 (2024) |
| MITSUBISHI TANABE PHARMA AMERICA, INC. | $6,660 | 8 | $0 (2024) |
| Biogen, Inc. | $6,391 | 13 | $0 (2023) |
| CSL Behring | $5,798 | 12 | $0 (2018) |
| Orion Corporation | $1,504 | 2 | $0 (2018) |
| ARGENX US, INC. | $129.09 | 2 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $125.00 | 1 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $60.57 | 1 | $0 (2018) |
| Teva Pharmaceuticals USA, Inc. | $28.20 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,730 | 8 | MITSUBISHI TANABE PHARMA AMERICA, INC. ($2,200) |
| 2023 | $18,653 | 22 | Amylyx Pharmaceuticals, Inc. ($14,192) |
| 2022 | $116.42 | 2 | ARGENX US, INC. ($102.42) |
| 2021 | $1,575 | 1 | Biogen, Inc. ($1,575) |
| 2020 | $3,900 | 1 | Biogen, Inc. ($3,900) |
| 2019 | $881.58 | 9 | Biogen, Inc. ($881.58) |
| 2018 | $18,712 | 43 | Alexion Pharmaceuticals, Inc. ($11,316) |
| 2017 | $4,504 | 11 | Alexion Pharmaceuticals, Inc. ($4,504) |
All Payment Transactions
97 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/16/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Immunology | ||||||
| 08/21/2024 | MITSUBISHI TANABE PHARMA AMERICA, INC. | RADICAVA ORS (Drug) | Consulting Fee | Cash or cash equivalent | $550.00 | General |
| Category: AMYOTROPHIC LATERAL SCLEROSIS | ||||||
| 08/21/2024 | MITSUBISHI TANABE PHARMA AMERICA, INC. | RADICAVA ORS (Drug) | Consulting Fee | Cash or cash equivalent | $550.00 | General |
| Category: AMYOTROPHIC LATERAL SCLEROSIS | ||||||
| 08/21/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $26.67 | General |
| Category: Neurology | ||||||
| 05/20/2024 | Teva Pharmaceuticals USA, Inc. | AJOVY (Biological) | Food and Beverage | In-kind items and services | $28.20 | General |
| Category: Central Nervous System | ||||||
| 03/13/2024 | MITSUBISHI TANABE PHARMA AMERICA, INC. | RADICAVA (Drug), RADICAVA ORS | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,100.00 | General |
| Category: AMYOTROPHIC LATERAL SCLEROSIS | ||||||
| 03/13/2024 | Amylyx Pharmaceuticals, Inc. | RELYVRIO (Drug) | Honoraria | Cash or cash equivalent | $900.00 | General |
| Category: NEUROLOGY | ||||||
| 01/24/2024 | Amylyx Pharmaceuticals, Inc. | RELYVRIO (Drug) | Honoraria | Cash or cash equivalent | $450.00 | General |
| Category: NEUROLOGY | ||||||
| 12/22/2023 | MITSUBISHI TANABE PHARMA AMERICA, INC. | Radicava ORS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,850.00 | General |
| Category: Amyotrophic Lateral Sclerosis | ||||||
| 12/20/2023 | Amylyx Pharmaceuticals, Inc. | RELYVRIO (Drug) | Honoraria | Cash or cash equivalent | $900.00 | General |
| Category: NEUROLOGY | ||||||
| 12/20/2023 | Amylyx Pharmaceuticals, Inc. | RELYVRIO (Drug) | Honoraria | Cash or cash equivalent | $450.00 | General |
| Category: NEUROLOGY | ||||||
| 12/15/2023 | MITSUBISHI TANABE PHARMA AMERICA, INC. | RADICAVA ORS (Drug) | Food and Beverage | In-kind items and services | $34.59 | General |
| Category: AMYOTROPHIC LATERAL SCLEROSIS | ||||||
| 12/15/2023 | MITSUBISHI TANABE PHARMA AMERICA, INC. | RADICAVA ORS (Drug) | Food and Beverage | In-kind items and services | $12.18 | General |
| Category: AMYOTROPHIC LATERAL SCLEROSIS | ||||||
| 12/13/2023 | Amylyx Pharmaceuticals, Inc. | RELYVRIO (Drug) | Honoraria | Cash or cash equivalent | $675.00 | General |
| Category: NEUROLOGY | ||||||
| 11/21/2023 | Amylyx Pharmaceuticals, Inc. | RELYVRIO (Drug) | Honoraria | Cash or cash equivalent | $900.00 | General |
| Category: NEUROLOGY | ||||||
| 10/21/2023 | Amylyx Pharmaceuticals, Inc. | RELYVRIO (Drug) | Honoraria | Cash or cash equivalent | $2,250.00 | General |
| Category: NEUROLOGY | ||||||
| 10/21/2023 | Amylyx Pharmaceuticals, Inc. | RELYVRIO (Drug) | Food and Beverage | Cash or cash equivalent | $31.27 | General |
| Category: NEUROLOGY | ||||||
| 10/09/2023 | Amylyx Pharmaceuticals, Inc. | RELYVRIO (Drug) | Honoraria | Cash or cash equivalent | $900.00 | General |
| Category: NEUROLOGY | ||||||
| 09/26/2023 | Biogen, Inc. | SPINRAZA (Biological) | Food and Beverage | In-kind items and services | $14.50 | General |
| Category: Neurology | ||||||
| 08/22/2023 | Amylyx Pharmaceuticals, Inc. | RELYVRIO (Drug) | Honoraria | Cash or cash equivalent | $1,350.00 | General |
| Category: NEUROLOGY | ||||||
| 05/19/2023 | Amylyx Pharmaceuticals, Inc. | RELYVRIO (Drug) | Honoraria | Cash or cash equivalent | $2,250.00 | General |
| Category: NEUROLOGY | ||||||
| 05/19/2023 | Amylyx Pharmaceuticals, Inc. | RELYVRIO (Drug) | Honoraria | Cash or cash equivalent | $732.49 | General |
| Category: NEUROLOGY | ||||||
| 04/22/2023 | Amylyx Pharmaceuticals, Inc. | RELYVRIO (Drug) | Food and Beverage | In-kind items and services | $95.69 | General |
| Category: NEUROLOGY | ||||||
| 04/21/2023 | Amylyx Pharmaceuticals, Inc. | RELYVRIO (Drug) | Honoraria | Cash or cash equivalent | $2,025.00 | General |
| Category: NEUROLOGY | ||||||
| 04/21/2023 | Amylyx Pharmaceuticals, Inc. | RELYVRIO (Drug) | Travel and Lodging | Cash or cash equivalent | $457.80 | General |
| Category: NEUROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 284 | 7,775 | $292,108 | $87,858 |
| 2022 | 8 | 286 | 7,258 | $251,226 | $78,417 |
| 2021 | 7 | 244 | 9,384 | $249,274 | $80,731 |
| 2020 | 8 | 180 | 5,543 | $164,110 | $52,105 |
Total Patients
994
Total Services
29,960
Medicare Billing
$299,112
Procedure Codes
33
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 20 | 7,300 | $124,100 | $36,145 | 29.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 80 | 179 | $78,402 | $27,108 | 34.6% |
| 64612 | Injection of chemical for paralysis of nerve muscles on side of face | Office | 2023 | 11 | 30 | $20,294 | $4,790 | 23.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 33 | 43 | $13,416 | $3,997 | 29.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 22 | 22 | $13,090 | $3,794 | 29.0% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 27 | 40 | $11,560 | $3,555 | 30.8% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 51 | 121 | $11,253 | $3,342 | 29.7% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2023 | 16 | 16 | $10,464 | $2,359 | 22.5% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2023 | 13 | 13 | $7,098 | $1,878 | 26.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 11 | 11 | $2,431 | $890.45 | 36.6% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 15 | 6,800 | $103,800 | $30,504 | 29.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 78 | 171 | $71,820 | $24,607 | 34.3% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2022 | 46 | 68 | $17,388 | $6,149 | 35.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 35 | 47 | $14,664 | $4,615 | 31.5% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2022 | 21 | 22 | $11,528 | $3,472 | 30.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 20 | 20 | $11,900 | $3,239 | 27.2% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 55 | 114 | $9,918 | $3,170 | 32.0% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2022 | 16 | 16 | $10,208 | $2,661 | 26.1% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2021 | 21 | 9,000 | $135,000 | $40,551 | 30.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 73 | 153 | $64,260 | $22,342 | 34.8% |
| 95886 | Needle measurement and recording of electrical activity of muscles of arm or leg complete study | Office | 2021 | 35 | 54 | $13,322 | $5,233 | 39.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 31 | 39 | $12,168 | $4,040 | 33.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 16 | 16 | $9,520 | $3,157 | 33.2% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2021 | 54 | 108 | $7,668 | $3,105 | 40.5% |
| 95910 | Nerve transmission studies, 7-8 studies | Office | 2021 | 14 | 14 | $7,336 | $2,305 | 31.4% |
About Dr. Michael Elliott, MD
Dr. Michael Elliott, MD is a Neurology healthcare provider based in Seattle, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1518986199.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Elliott, MD has received a total of $52,072 in payments from pharmaceutical and medical device companies, with $3,730 received in 2024. These payments were reported across 97 transactions from 11 companies. The most common payment nature is "Honoraria" ($27,122).
As a Medicare-enrolled provider, Elliott has provided services to 994 Medicare beneficiaries, totaling 29,960 services with total Medicare billing of $299,112. Data is available for 4 years (2020–2023), covering 33 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Seattle, WA
- Active Since 07/18/2006
- Last Updated 05/18/2021
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1518986199
Products in Payments
- RELYVRIO (Drug) $15,542
- SOLIRIS (Drug) $11,352
- Hizentra (Biological) $5,798
- Radicava ORS (Drug) $3,850
- RADICAVA ORS (Drug) $1,697
- RADICAVA (Drug) $1,100
- TREMFYA (Drug) $125.00
- VYVGART (Drug) $102.42
- SPINRAZA (Biological) $34.60
- AJOVY (Biological) $28.20
- VYVGART HYTRULO (Drug) $26.67
- UBRELVY (Drug) $14.00
- Radicava (Drug) $12.74
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Seattle
Dr. Pavle Repovic, Md, Phd, MD, PHD
Neurology — Payments: $1.2M
Neurology $1.2M
Nathaniel Watson, Md, MD
Neurology — Payments: $352,101
Neurology $352,101
Mariko Kita, Md, MD
Neurology — Payments: $243,050
Neurology $243,050
Kyra Becker
Neurology — Payments: $239,174
Neurology $239,174
Christyn Edmundson, Md, MD
Neurology — Payments: $226,530
Neurology $226,530
Pravin Khemani, Md, MD
Neurology — Payments: $199,884
Neurology $199,884